epoprostenol

(redirected from Veletri)

epoprostenol

[e″po-pros´tĕ-nol]

name for prostacyclin when used pharmaceutically; it is used in the form of the sodium salt as an inhibitor of platelet aggregation for blood contacting nonbiological systems, as in renal dialysis, as a pulmonary antihypertensive, and as a vasodilator.

pros·ta·cy·clin

(pros'tă-sī'klin),

A potent natural inhibitor of platelet aggregation and a powerful vasodilator.

Synonym(s): epoprostenol, epoprostenol sodium

Beraprost

An oral prostacyclin PGI2 analogue with vasodilator, antiplatelet, and cytoprotective effects, used to manage pulmonary arterial hypertension. Beraprost improves exercise capacity and symptoms in NYHA-functional class-II and -III patients with PAH and, in particular, in those with primary pulmonary hypertension.

Adverse effects
Headache, facial flushing, vasodilation.

epoprostenol

Prostacyclin. A powerful inhibitor of clumping of blood platelets and thus of blood clotting. It is used with heart-lung (cardiopulmonary bypass) machines and artificial kidneys (dialysis machines) to preserve the platelets in the blood being pumped through them. Epoprostenol also widens (dilates) arteries. A brand name is Flotan.

Mentioned in ?

References in periodicals archive ?

Actelion Acquisition: The acquisition gives JNJ five currently-marketed therapies (Opsumit, Tracleer, Uptravi, Veletri and Ventavis) for the treatment of pulmonary hypertension and two currently-marketed specialty products, Valchlor gel (cutaneous T-cell lymphoma) and Zavesca (Gaucher disease in the U.S./Nieman-Pick disease in Europe).

Fitch Rates Johnson & Johnson's Notes Offering 'AAA'; Outlook Stable

Actelion is a highly profitable life science firm as a result of our leading franchise in pulmonary arterial hypertension (PAH), where our three marketed products Tracleer, Ventavis and Veletri continue to bring significant value to patients.

Biomarketing strategy and tactics 101: part II of III

27 August 2010 - Actelion Pharmaceuticals US Inc, part of Swiss Actelion Ltd (VTX: ATLN), said on Wednesday that the US Food and Drug Administration (FDA) has approved the brand name VELETRI for the company's epoprostenol for injection therapy.

VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease.

VELETRI is an improved formulation of epoprostenol that offers greater convenience to patients than other epoprostenol formulations, the company said.

In conjunction with the launch of VELETRI, Actelion opened its fourth PAH patient registry in the US.

Actelion said it will also provide further information on VELETRI at the American Heart Association Scientific Sessions 2010 in Chicago with a poster entitled "Biocomparability of Two Formulations of Epoprostenol, Epoprostenol for Injection (ACT-385781A) And Flolan, Via Pharmacokinetic Assessment of Two Primary Metabolites."

Actelion says FDA OKs brand name VELETRI for epoprostenol for injection therapy

(19) The Italian military scenes in Don Alvaro o la fuerza del sino take place in Veletri, near the place where in 1744 Austrian Imperial forces were defeated by Spanish and Neapolitan troops led by Carlos de Borbon, King of Naples.

Meyerbeer's L'Africaine: French grand opera and the Iberian exotic

-- Veletri(TM) (tezosentan): With partner Actelion Ltd., announced the second pivotal Phase III clinical trial of Veletri -- an intravenous dual endothelin receptor antagonist -- did not meet its primary objective of significantly improving symptoms (dyspnea, or shortness of breath) associated with acute heart failure.

GENENTECH REPORTS 33% INCREASE IN PRODUCT SALES FOR 2ND QTR

Tezosentan (Veletri), the first dual en dothelin receptor antagonist, offered clinically significant hemodynamic benefits in a randomized double-blind multicenter trial involving 292 .patients hospitalized for acute decompensated heart failure.